Cell Design Labs
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cell Design Labs
Deal Watch: Gilead Partners With Carna On Small Molecule IO Drug Development
Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.
The Case For CAR-T Grows As Responses Hold Up Longer Term
Novartis and Gilead longer-term data show largely steady response and survival rates, shoring up the clinical and commercial case for their products and justifying continued investment in T-cell therapies. The CAR-T pioneers discuss their progress, including with allogeneic platforms, with Scrip at ASH.
Milligan’s Retirement Means New CEO For New Gilead
While Milligan’s year-end departure topped the news, Gilead posted solid sales growth for Yescarta, got the HIV franchise back to growth and saw HCV’s decline largely stabilize. CSO McHutchison, meanwhile, predicted that selonsertib could be first to market in NASH.
Deal Watch: Gilead Continues To Add To IO Armamentarium In Collaboration With Gadeta
Deal through Kite Pharma subsidiary focuses on developing gamma delta T-cell receptor therapies. Sanofi inks SHP2 cancer collaboration with Revolution, while Vical considers its strategic options.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.